Beryl Drugs
BSE: BERLDRG · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Beryl Drugs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Beryl Drugs Limited is an Indore-based pharmaceutical company specialising in the manufacturing and marketing of branded and generic formulations. The company focuses on the production of small volume injectables, including vials, ampoules, and dry powder injections, alongside liquid orals.
Business Model
The company generates revenue through the manufacturing and sale of pharmaceutical products across therapeutic segments such as antibiotics, analgesics, and nutritional supplements. It serves both domestic retail markets and institutional supply channels.
Growth Outlook
Growth is driven by the company's focus on the niche parenteral segment and its adherence to Good Manufacturing Practices to maintain quality standards. Future prospects rely on expanding its presence within the domestic healthcare market and institutional supply tenders.
Key Risks
- Regulatory Compliance. Failure to maintain Good Manufacturing Practices could lead to operational disruptions or loss of manufacturing licences.
- Market Competition. The company faces intense competition from larger pharmaceutical players in the generic and parenteral segments.
- Input Cost Volatility. Fluctuations in the prices of active pharmaceutical ingredients and raw materials may impact profit margins.
- Institutional Dependency. Reliance on institutional supplies makes the company vulnerable to changes in government procurement policies and tender cycles.
Start your research today
Unlock AI insights, financials, peers and live data on Beryl Drugs and 5,000+ companies — free.
Key Metrics
REVENUE
₹19 Cr
TTM · standalone
NET PROFIT
₹0.76 Cr
TTM · standalone
EPS
₹1.50
TTM · standalone
RETURN ON EQUITY
7.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
18.9%
TTM · standalone
P/E
14.1x
Q4 FY26 · standalone
EV/EBITDA
3.3x
Q4 FY26 · standalone
EBITDA MARGIN
19.3%
TTM · standalone
NET PROFIT MARGIN
10.9%
Q4 FY26 · standalone
DEBT TO EQUITY
0.2x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Beryl DrugsBERLDRG | ₹12 Cr | 15.28 | 3.77 | 5.3% | 19.3% | 7.9% | 18.9% | -9.1% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Beryl Drugs
BSE: BERLDRG · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Beryl Drugs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Beryl Drugs Limited is an Indore-based pharmaceutical company specialising in the manufacturing and marketing of branded and generic formulations. The company focuses on the production of small volume injectables, including vials, ampoules, and dry powder injections, alongside liquid orals.
Business Model
The company generates revenue through the manufacturing and sale of pharmaceutical products across therapeutic segments such as antibiotics, analgesics, and nutritional supplements. It serves both domestic retail markets and institutional supply channels.
Growth Outlook
Growth is driven by the company's focus on the niche parenteral segment and its adherence to Good Manufacturing Practices to maintain quality standards. Future prospects rely on expanding its presence within the domestic healthcare market and institutional supply tenders.
Key Risks
- Regulatory Compliance. Failure to maintain Good Manufacturing Practices could lead to operational disruptions or loss of manufacturing licences.
- Market Competition. The company faces intense competition from larger pharmaceutical players in the generic and parenteral segments.
- Input Cost Volatility. Fluctuations in the prices of active pharmaceutical ingredients and raw materials may impact profit margins.
- Institutional Dependency. Reliance on institutional supplies makes the company vulnerable to changes in government procurement policies and tender cycles.
Start your research today
Unlock AI insights, financials, peers and live data on Beryl Drugs and 5,000+ companies — free.
Key Metrics
REVENUE
₹19 Cr
TTM · standalone
NET PROFIT
₹0.76 Cr
TTM · standalone
EPS
₹1.50
TTM · standalone
RETURN ON EQUITY
7.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
18.9%
TTM · standalone
P/E
14.1x
Q4 FY26 · standalone
EV/EBITDA
3.3x
Q4 FY26 · standalone
EBITDA MARGIN
19.3%
TTM · standalone
NET PROFIT MARGIN
10.9%
Q4 FY26 · standalone
DEBT TO EQUITY
0.2x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26